Howard George, Muntner Paul, Lackland Daniel T, Plante Timothy B, Cushman Mary, Stamm Brian, Judd Suzanne E, Howard Virginia J
Department of Biostatistics (G.H., S.E.J.), School of Public Health, University of Alabama at Birmingham.
Department of Epidemiology (P.M., V.J.H.), School of Public Health, University of Alabama at Birmingham.
Stroke. 2025 Jan;56(1):105-112. doi: 10.1161/STROKEAHA.124.048385. Epub 2024 Dec 9.
The focus for reducing hypertension-related cardiovascular disease is the management of blood pressure. Limited data are available on the potential benefit of delaying the onset of hypertension.
Stroke-free Black and White participants from the REGARDS cohort study (Reasons for Geographic and Racial Differences in Stroke; recruited 2003-2007) were followed through 2022 for incident stroke events. Participants were stratified by duration of recognized hypertension: normotensive (0 years), ≤5 years, 6 to 20 years, or 21+ years. The baseline systolic blood pressure (SBP), the number of classes of antihypertensive medications, and the risk of incident stroke were assessed by duration strata adjusting for demographics, cerebrovascular risk factors, SBP, and use of antihypertensive medications (where appropriate).
Of 30 239 study participants, we included 27 310 participants (mean age, 65 years; 45% male), followed a median of 12.4 years, during which 1763 incident stroke events occurred. On average, participants with hypertension duration ≤5 years, 6 to 20 years, and 21+ years were taking 1.68 (95% CI, 1.65-1.71), 2.04 (95% CI, 2.01-2.07), and 2.28 (95% CI, 2.25-2.31) classes of antihypertensive medications, respectively. The adjusted mean SBP level was higher with each increasing duration of recognized hypertension (0, ≤5, 6-20, and 21+ years): 123.9 mm Hg (95% CI, 123.3-124.6), 129.7 mm Hg (95% CI, 129.1-130.2), 131.7 mm Hg (95% CI, 130.6-131.5), and 132.6 mm Hg (95% CI, 132.0-133.1). Compared with normotensive individuals, the hazard for incident stroke increased from 1.31 (95% CI, 1.05-1.63) for ≤5 years duration, 1.50 (95% CI, 1.21-1.87) for 6 to 20 years duration, and 1.67 (95% CI, 1.32-2.10) for 21+ years duration.
Longer duration of recognized hypertension was associated with more classes of antihypertensive medications, higher mean SBP, and higher stroke risk even after adjustment for age and SBP. Collectively, this suggests that delaying the onset of hypertension could reduce the burden of stroke.
降低高血压相关心血管疾病的重点在于血压管理。关于延迟高血压发病的潜在益处的数据有限。
对REGARDS队列研究(卒中地理和种族差异原因研究;2003 - 2007年招募)中无卒中的黑人和白人参与者进行随访,直至2022年,观察卒中事件的发生情况。参与者按已确诊高血压的病程分层:血压正常(0年)、≤5年、6至20年或21年以上。通过对人口统计学、脑血管危险因素、收缩压和降压药物使用情况(如适用)进行调整,按病程分层评估基线收缩压(SBP)、降压药物类别数量和卒中发病风险。
在30239名研究参与者中,我们纳入了27310名参与者(平均年龄65岁;45%为男性),随访中位时间为12.4年,在此期间发生了1763例卒中事件。平均而言,高血压病程≤5年、6至20年和21年以上的参与者分别服用1.68(95%CI,1.65 - 1.71)、2.04(95%CI,2.01 - 2.07)和2.28(95%CI,2.25 - 2.31)类降压药物。随着已确诊高血压病程每增加一个阶段(0、≤5、6 - 20和21年以上),调整后的平均SBP水平升高:123.9 mmHg(95%CI,123.3 - 124.6)、129.7 mmHg(95%CI,129.1 - 130.2)、131.7 mmHg(95%CI,130.6 - 131.5)和132.6 mmHg(95%CI,132.0 - 133.1)。与血压正常个体相比,卒中发病风险在病程≤5年时为1.31(95%CI,1.05 - 1.63),6至20年时为1.50(95%CI,1.21 - 1.87),21年以上时为1.67(95%CI,1.32 - 2.10)。
即使在调整年龄和收缩压后,已确诊高血压的病程较长仍与更多类别的降压药物、更高的平均收缩压和更高的卒中风险相关。总体而言,这表明延迟高血压的发病可能减轻卒中负担。